The planned withdrawal follows the January failure of a Phase III trial to back up the study used for Lartruvo's accelerated approval. Following the announcement, the FDA and EMA recommended no new patients receive the drug.
A Phase III trial of Lartruvo, which won accelerated approval for soft-tissue sarcoma in 2016, failed to confirm an overall survival benefit.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Sarcoma accounts for 15 percent of childhood cancer cases but only about one percent of adult cases.